Financings

Arsanis Inc. closed a $10 million Series A round.

NeuroPhage Pharmaceuticals Inc. secured $12.4 million in Series B funding.

Tengion Inc. raised $31.4 million in a PIPE.

Deals

Daiichi Sankyo Co. Ltd. bought Plexxikon Inc. for $806 million up front and $130 million in milestones.

Intra-Cellular Therapies Inc. inked a potential $750 million schizophrenia drug deal with Takeda Pharmaceutical Co. Ltd.

Lycera Corp. partnered with Merck & Co. Inc. to develop against T-helper 17 for $12 million up front and up to $295 million in milestones.

Samsung Group and Quintiles Transnational Corp. entered a $266 million joint venture.

TiGenix NV agreed to merge with Cellerex SA in an all-share deal valued at €58 million (US$79.7 million).

. . . And More

Amylin Pharmaceuticals Inc., Alkermes Inc. and Eli Lilly and Co. reported that Bydureon (exenatide once-weekly) fell short in a head-to-head study against once-daily Victoza (liraglutide, Novo Nordisk A/S).

BioCryst Pharmaceuticals Inc. received a $55 million government contract to complete Phase III development of peramivir.

Forest Laboratories Inc. got an FDA nod for chronic obstructive pulmonary disease drug Daliresp (roflumilast).

GTx Inc. discontinued work on prostate cancer toremifene after ending its partnership with Ipsen Group SA.

InterMune Inc.'s idiopathic pulmonary fibrosis drug pirfenidone won approval in Europe.

Ligand Pharmaceuticals Inc. and GlaxoSmithKline plc gained full FDA approval for Promacta (eltrombopag) in immune thrombocytopenic purpura.

Merck KGaA got a complete response letter for multiple sclerosis drug cladribine.

Novavax Inc. and VaxInnate Inc. each received part of a $215 million award from the Department of Health and Human Services for vaccine work.

Pharming NV and partner Santarus Inc. got a refuse-to-file notice from the FDA for C1 inhibitor Rhucin in hereditary angioedema.

Protalix BioTherapeutics Inc. fell 18.5 percent on a complete response letter for Gaucher's drug taliglucerase.

Renovo plc is closing up shop after Phase III failure of scar prevention candidate Juvista.

Seattle Genetics Inc. filed a biologics license application for brentuximab vedotin in Hodgkin lymphoma and anaplastic large cell lymphoma.

Targacept Inc. and GlaxoSmithKline plc ended a potential $1 billion alliance.